56705-84-1

Usage

Uses

Used in Chemical Industry:
4-(3-methylphenoxy)aniline is used as a key intermediate in the synthesis of various organic compounds, leveraging its reactive structure to facilitate the creation of a broad spectrum of chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 4-(3-methylphenoxy)aniline serves as an essential intermediate for the production of dyes and pharmaceuticals, contributing to the development of new drugs and improving existing ones.
Used in Research and Development:
4-(3-methylphenoxy)aniline is utilized in research settings to explore its potential biological activities and pharmacological properties, with the aim of discovering new applications and enhancing its therapeutic value.

InChI:InChI=1/C13H13NO/c1-10-3-2-4-13(9-10)15-12-7-5-11(14)6-8-12/h2-9H,14H2,1H3

Upstream product

• 108-39-4 3-methyl-phenol 
• 586-78-7 para-nitrophenyl bromide 
• 350-46-9 4-Fluoronitrobenzene 
• 2303-25-5 3-methyl-4'-nitrodiphenyl ether 

Downstream Products

• 56884-86-7 2-(4-nitro-phenyl)-3-(4-m-tolyloxy-phenyl)-thiazolidin-4-one 
• 192768-36-8 {(R)-1-[(4-m-Tolyloxy-phenylamino)-methyl]-2-tritylsulfanyl-ethyl}-carbamic acid tert-butyl ester 
• 1311136-62-5 (5R)-5-methyl-3-{4-[(3-methylphenyl)oxy]phenyl}-2,4-imidazolidinedione 
• 65948-19-8 2-Amino-6-phenoxybenzothiazole 
• 129121-42-2 2-amino-6-(3-methylphenoxy)benzothiazole 
• 860744-86-1 acetic acid-[4-(3-methyl-4-nitro-phenoxy)-2-nitro-anilide] 
• 860585-93-9 4-(3-methyl-4-nitro-phenoxy)-2-nitro-aniline 
• 873977-84-5 acetic acid-[4-(4-bromo-3-methyl-phenoxy)-2-nitro-anilide] 
• 873977-67-4 acetic acid-[4-(4-chloro-3-methyl-phenoxy)-2-nitro-anilide] 
• 876496-53-6 acetic acid-(2-nitro-4-m-tolyloxy-anilide) 
• 873980-25-7 4-(4-bromo-3-methyl-phenoxy)-2-nitro-aniline 
• 873980-51-9 4-(4-chloro-3-methyl-phenoxy)-2-nitro-aniline 
• 873977-88-9 acetic acid-[4-(4-bromo-3-methyl-phenoxy)-anilide] 
• 873977-71-0 acetic acid-[4-(4-chloro-3-methyl-phenoxy)-anilide] 

Relevant academic research and scientific papers

Discovery of 1,2,4-triazole-1,3-disulfonamides as dual inhibitors of mitochondrial complex II and complex III

Respiratory chain succinate-ubiquinone oxidoreductase (SQR or complex II) and ubihydroquinone-cytochrome (cyt) c oxidoreductase (cyt bc1 or complex III) have been demonstrated as the promising targets of numerous antibiotics and fungicides. As a continuation of our research work on the development of new fungicides, a series of 1,2,4-triazole-1,3-disulfonamide derivatives with dual functions targeting both SQR and cyt bc1 were designed and synthesized by coupling diverse diphenyl ether moieties with triazolesulfonamide units. These newly synthesized compounds were characterized by elemental analyses, 1H NMR and ESI-MS spectrometry. The in vitro assay indicated that most of the synthesized compounds displayed good inhibition against porcine succinate-cytochrome reductase (SCR) with IC50 values ranging from 3.2 to 81.8 μM, revealing much higher activity than that of the commercial control amisulbrom whose IC50 value is 93.0 μM. Further evaluation against the respective SQR and cyt bc1 indicated that most compounds exhibited SQR-inhibiting activity as well as cyt bc1-inhibiting activity, but the inhibition potency against SQR is much higher than that against cyt bc1, showing that the SCR inhibition might be contributed greatly by the SQR inhibition. The further antibacterial evaluation against Xanthomonas oryzae pv. oryzae revealed that four compounds showed excellent potency at the concentration of 20 μg mL-1. In particular, compounds 6h and 6j exhibited much better antibacterial activity than the commercial control bismerthiazol in terms of their EC50. Impressively, 6j has an EC90 of 33.62 μg mL-1, more than 10-fold higher than that of bismerthiazol.

Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase

Leukotriene B4 (LTB4) is a potent pro-inflammatory mediator that has been implicated in the pathogenesis of multiple diseases, including psoriasis, inflammatory bowel disease, multiple sclerosis and asthma. As a method to decrease the level of LTB4 and possibly identify novel treatments, inhibitors of the LTB4 biosynthetic enzyme, leukotriene A4 hydrolase (LTA4-h), have been explored. Here we describe the discovery of a potent inhibitor of LTA4-h, arylamide of glutamic acid 4f, starting from the corresponding glycinamide 2. Analogs of 4f are then described, focusing on compounds that are both active and stable in whole blood. This effort culminated in the identification of amino alcohol 12a and amino ester 6b which meet these criteria.

Inhibitors of protein kinases

Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

NOVEL HETEROCYCLIC AMIDE DERIVATIVES HAVING DIHYDROOROTATE DEHYDROGENASE INHIBITING ACTIVITY

Novel heterocyclic amide derivatives having pharmacological effects, that is, compounds represented by the general formula (1) or salts thereof: (1) wherein X1-X2 is S-CH2 or the like; R1 is alkyl or the like; p is 0 to 7; R2 is hydrogen, alkyl, or the like; R3 is hydrogen, alkyl, or the like; Y1-Y2 is CH=CH or the like; R4 is halogeno, alkyl, or the like; q is 0 to 4; and R5 is halogeno, hydrogen, alkyl, or the like.

Derivatives of quinoline as inhibitors for MEK

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof. wherein: n is 0-1; X and Y are independently selected from -NH-, -O-, -S-, or -NR8- where R8 is alkyl of 1-6 carbon atoms and X may additionally comprise a CH2 group; R7 is a group (CH2)mR9 where m is 0,or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more specified groups; R1, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. Compounds are useful as pharmaceuticals for the inhibition of MEK activity.

Diarylether inhibitors of farnesyl-protein transferase

The design and synthesis of simple nonpeptide inhibitors of farnesyl-protein transferase (FTase) are described. Cysteine-derived diarylether frameworks are appropriate structural replacements for the C-terminal tetrapeptide portion of the Ras protein, and possess in vitro potency against FTase. Inhibitory activity is dependent on the ring-substitution pattern, and does not require the presence of a C-terminal carboxylate group.